Fortrea Holdings (FRA:K67) Debt-to-Revenue : 0.45 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Fortrea Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €13 Mil. Fortrea Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1,105 Mil. Fortrea Holdings's annualized Revenue for the quarter that ended in Jun. 2024 was €2,461 Mil. Fortrea Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.45.

Fortrea Holdings Debt-to-Revenue Historical Data

The historical data trend for Fortrea Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Debt-to-Revenue Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

0.03

0.02

0.54

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Revenue	Get a 7-Day Free Trial							0.58	0.54	0.54	0.64	0.45

Competitive Comparison of Fortrea Holdings's Debt-to-Revenue

For the Biotechnology subindustry, Fortrea Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortrea Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Debt-to-Revenue falls into.

Fortrea Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Fortrea Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(41.815	+	1496.911)	/	2850.953
	=	0.54

Fortrea Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(12.542	+	1105.138)	/	2461.48
	=	0.45

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.

Fortrea Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

FTRE:USA FTRE1:Mexico

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines